The RestoreX™ is the subject of a patent validating the exclusivity of the dual traction force technology. It is manufactured in the USA by PathRight Medical, based in Orem, Utah.
The RestoreX™ is marketed by Med'Arte a French company specializing in the sale of medical devices for Urology to healthcare institutions.
-
2 extension rods only
48,00€
-
Pelvic ring
36,00€
-
Lower clamp
48,00€
-
Upper clamp
60,00€
-
SHIPPING COST
50,00€
The RestoreX™ was invented by Dr. Landon TROST, an American Urologist specializing in Lapeyronie's disease and author of multiple studies and clinical recommendations concerning this pathology. He has no professional or financial links with PathRight Medical, and his clinical publications concerning Lapeyronie's disease or the RestoreX™ have all been carried out in accordance with the ethical and scientific procedures defined by the AUA (American Urology Association)
The axial traction force is between 2.5 and 3 Kg and that on the counter-curvature between 4.5 and 5 Kg. The power of these tractions is the main reason for the RestoreX™'s effectiveness and has no equivalent among other traction-therapy devices. To ensure that the penis does not escape during traction, the glans is clamped onto a very wide base, enabling it to be firmly secured and, to avoid pain, the pressure to be distributed over a large contact area.
The RestoreX™ is effective for correcting penile curvature but also for treating hourglass yards.
The RestoreX™ is the only treatment to have shown tangible results concerning recovery of penile length 1b, 2b.
The RestoreX™ benefits from CE marking, which classifies it as a genuine Medical Device.
Comparison of penile traction devices
Sources: Websites and user manuals of various manufacturers
| RestoreX™ | AndroPenis | X4 | PeniMaster | |
|---|---|---|---|---|
| Treatment duration | 30 to 60 min/day | 9 hours/day | 5 hours/day | 3 hours/day |
| Invention developed by a doctor specializing in Lapeyonie disease | ||||
| Double traction force | ||||
| Focusing traction on the deformation zone | ||||
| Prospective randomized clinical trials for Lapeyronie's disease | ||||
| Randomized clinical trials for post-prostatectomy lengthening of the penis | ||||
| FDA approval and CE marking | ||||
M.J. Ziegelmann & al. - 2019: Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial
110 patients, mean age 58 years, Lapeyronie anteriority: 49 months, mean curvature 59.3 degrees.
4 groups: 1 control group (number = 27) and 3 other RestoreX ™ groups with daily sessions of use: group 1 (number =28) → 30 min session, group 2 (number =28) → 60 min session, group 3 (number =27) → 90 min session. RestoreX use time divided equally (50/50) into axial traction and counter-curvature
A. Results at 3 months, average use 47mn/day
- Curvature reduced by 17.2° or 28%, for 77% of patients who responded to treatment (control group
= +1.3°). Of these 77%, i.e. around 4 out of 5 men, who saw a reduction in curvature, 28% achieved a reduction in curvature of 20°, and for 48% of these 77%, the reduction in curvature was greater than 20°. - Recovery of penis length: +1.6cm or +11% for 94% of patients who responded to treatment
(control group = +0.3cm). - Improvement in erectile function according to IIEF score of 4.3 (control group = 0.7).
- 47% of patients were unable to have sexual intercourse with their partner due to insufficient penile tumescence: after 12 weeks of treatment, 80% of them reported being able to penetrate their partner.
- No adverse effects were noted (haematomas, petechiae,...)
- 100% of patients who had already tried another traction-therapy device said they preferred the RestoreX™.
B. 2 additional phases of clinical study at 6 (n=64) and 9 (n=63) months follow-up, daily use
average 31 min/day
- 63% of patients reported improvements in curvature and length (+0.5 cm).
- The International Index of Erectile Function (IIEF) questionnaire score was also increased.
- 84% of patients continued to use RestoreX™ after 9 months.
The mean curvature observed in this study was 59.3°, which virtually classifies this value as severe (> 60°). The mean curvature, as reported in clinical studies, is generally between 30° and 50°.
The mean anteriority of Lapeyronie's disease is 49 months which implies an exponential hardness over time of the fibrosis plaque as well as increasing retraction of the albuginea.
These 2 very demanding criteria represent a real challenge for the RestoreX™.
23% of patients saw no improvement. We tried to understand why these patients didn't respond, and the explanations are varied: some weren't using the device correctly, others weren't using it at all, and still others were probably doing everything right but getting no response. We don't know why this last group didn't respond.
The reduction in curvature at 3 months is 17.2°, or 28% improvement, which represents a considerable evolution. Degrees are an absolute way of measuring angulation, while percentage is a relative value that varies according to the amount of curvature.
For example, if a person has a curvature of 100° that will be reduced by 40° with the RestoreX™, they will see an improvement of 60° and also of 60%. But if another person whose curvature is 40° registers, as in the clinical study, an improvement of 20°, they will recognize an improvement of 50% over the original curvature.
